In a phase 1/2 study evaluating the triplet combination of magrolimab/AZA/VEN for ND and R/R AML patients, the ND cohort (n = 41) exhibited a high prevalence of adverse risk disease (92%) and TP53 mutations (66%). This evidence concerns the gene TP53 and acute myeloid leukemia.